You wouldn't want your patients to take the placebo first since those patients had a better OS outcome?
Of course it has low toxicity. But of course you know that all the trial patients were on SOC (chemo and radiation) per the trial protocol, right? So you would be giving your patients the same toxic chemo prior to putting them on DCVax.
Did you share the results of the 2018 blended data, which were better but also included the control arm in the mOS of the ITT population? Why would mOS go down when you remove the 65 control patients? Please show your math. You had to take math in med school, right?